Navigation Links
Intense chemotherapy wards off recurrence in half of mantle cell lymphoma patients after seven years
Date:12/9/2008

SAN FRANCISCO - More than half of younger mantle cell lymphoma patients who received an intensive regimen of chemotherapy as frontline treatment remain in remission seven years later, researchers at The University of Texas M. D. Anderson Cancer Center report today at the 50th annual meeting of the American Society of Hematology.

Among patients 65 or younger, 52 percent survived without disease recurrence at a median of seven years of follow-up, said first author Jorge Romaguera, M.D., professor in M. D. Anderson's Department of Lymphoma and Myeloma. Overall survival for this subgroup was 68 percent.

"There is some disagreement about whether these younger patients should receive a bone marrow transplant as frontline therapy rather than chemotherapy," Romaguera said. "Our results with chemotherapy are as good as any transplant data. We don't believe a transplant is necessary as a first treatment in newly diagnosed mantle cell lymphoma."

Mantle cell lymphoma is one of the most lethal versions of non-Hodgkin lymphoma. Romaguera and colleagues have followed 97 patients for up to nine years who received rituximab plus a combination of chemotherapies known as hyperCVAD, alternated with rituximab plus high-dose methotrexate/cytarabine in 6-8 cycles.

Out of those patients, 87 percent achieved either a complete response or unconfirmed complete response after six cycles. Of 65 patients who were 65 or younger, 30 relapsed. Of 32 patients older than 65, a total of 23 relapsed.

Overall survival for the entire group, including all ages up to 80 years, was 60 percent; 43 percent were at failure-free survival, with no recurrence of the disease, at seven years of median follow-up.

Survival is about the same for patients who undergo stem cell transplantation, Romaguera said. No randomized studies between the chemotherapy regimen, stem cell transplants or the chemotherapy plus stem cell transplant have been done.

About 3,500 new cases of mantle cell lymphoma are diagnosed in the United States annually. The average age of diagnosis is the mid-sixties and median survival is about four years.


'/>"/>

Contact: Scott Merville
smerville@mdanderson.org
713-792-0661
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert  

Related medicine news :

1. Ultra-fast, ultra-intense laser has clean-cut advantage
2. Itching Not a Less Intense Form of Pain
3. Chemotherapy may be culprit for fatigue in breast cancer survivors
4. Replidyne Pipeline Featured at 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
5. To evade chemotherapy, some cancer cells mimic stem cells
6. New chemotherapy regimen prolongs survival in difficult-to-treat childhood brainstem gliomas
7. PET scans can accurately detect a breast tumors response to chemotherapy
8. Chemotherapy with gemcitabine delays progression of operable pancreatic cancer
9. Medicare modernization act did not change chemotherapy as feared
10. HER-2 status predicts success of chemotherapy in breast cancer treatment, study finds
11. Cancer conflict with chemotherapy treatment
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Intense chemotherapy wards off recurrence in half of mantle cell lymphoma patients after seven years
(Date:7/20/2017)... ... 20, 2017 , ... Remote Medical Technologies (RMT) is announcing ... with each system installation. RMT’s iMedHD2™ Telepathology and Teleultrasound ... and immediate decision-making requirements. While never sharing IP addresses, RMT has made ...
(Date:7/20/2017)... ... July 20, 2017 , ... Doctors on Liens, the leading network ... Horine Chiropractic , directed by Dr. Russell Horine, DC to their exclusive list of ... with Dr. Russell Horine serving as the clinic director and his son Dr. Lee ...
(Date:7/20/2017)... ... July 20, 2017 , ... Girl Up ... House and Senate legislation in support of providing girls access to education in ... H.R. 2408, the “Protecting Girls’ Access to Education in Vulnerable Settings Act.” Yesterday, ...
(Date:7/20/2017)... ... July 20, 2017 , ... The Dermatology Clinic announced today the ... his BS in Biology from LSU, graduating summa cum laude. He attended Emory University ... his residency in St. Louis, Dr. Dunbar moved to New York to complete an ...
(Date:7/20/2017)... ... July 20, 2017 , ... There’s a lot of confusing lingo out ... are the same thing. But it’s crucial to understand both the differences and similarities ... to Kaixuan Liu, MD, PhD, founder and president of Atlantic Spine Center . ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... 2017  Sysmex America, Inc., a leading provider ... as well as middleware information systems technology, today ... quality assurance easier and more risk free than ... for the innovation that it delivers to the ... assurance processes to a new level with automated, ...
(Date:7/10/2017)... 2017 The Institute for In Vitro Sciences ... recipient of a VITROCELL® inhalation exposure system thanks to ... The device, which is designed to replace animals in ... cells to airborne test materials in an environment that ... system for testing combustible tobacco products, as well as ...
(Date:7/6/2017)... ThriveRx, the nutrition division of Diplomat Specialty Infusion Group, is ... nutrition support. To celebrate its anniversary, ThriveRx recently launched a ... new look with improved organization to create the best user experience for ... ... "We,ve made several great strides ...
Breaking Medicine Technology: